Refining 'total therapy' for myeloma.

摘要

In this issue of Blood, Nair and colleagues report similar results with Total Therapy 3 and their subsequent trial, replacing VTD/TD consolidation/maintenance by VRD despite the higher incidence of adverse prognostic features in the current study.